Volume Spike Investor » AMGN

Top Day Trader Alerts (AMGN, ACLI, CTIC, CERS, ERTS, LCAV, NBG, SQNM)

247admin — Tue, 09 Feb 2010 13:59:48 +0000

These are some of the top trading stocks seen on price and volume moves for day traders and active traders:

Amgen Inc. (NASDAQ: AMGN) is trading up this morning by 2.25% at $58.75 on almost 200,000 shares on its report that its Phase III head-to-head trial evaluating Denosumab met its primary and secondary endpoints versus Zometa in a 1900+ study in the treatment of advanced prostate cancer that has progressed to bone metastases.

American Commercial Lines Inc. (NASDAQ: ACLI) is soaring as the top gainer on NASDAQ but on this volume. The headline earnings were $1.09 EPS vs. $0.06 as revenue fell 16% to $226.9 million versus estimates of $222.5 million. The revenue drop was blamed on commodities shipped by transportation customers and lower tow revenues as tons/mile volume declined was down 1.4%. A large short interest exists here at 1.077 million shares or 11.5% of the float. Shares are up 26% at $20.48 but on 13,000 shares.

Cell Therapeutics, Inc. (NASDAQ: CTIC) is up after a huge sell-off yesterday after the FDA postponed its Oncologic Drugs Advisory Committee Meeting to review Pixantrone due to severe snow conditions around the nation’s capital. Shares closed at $0.64 and are indicated up around $0.78 on 1.9+ million shares. Shares were as high as $0.84 in earlier trading.

Cerus Corporation (NASDAQ: CERS) is trading up 16%, even above earlier indications, at $2.35 on 81,000 shares after the company reported positive results of its Phase 1 clinical trial of INTERCEPT red blood cells and on its report that it will collaborate with the French National Transfusion Service on INTERCEPT red blood cell development.

Electronic Arts Inc. (NASDAQ: ERTS) down 7.8% at $16.12 on 700,000 shares; very actively traded to downside last night; this after earnings were mostly in line with estimates but the company lowered guidance all the way out to Fiscal March-2011.

LCA-Vision Inc. (NASDAQ: LCAV) beat earnings this morning but just with a more narrow loss (-$0.19 EPS). We have not paid attention to the rest of the data from the call but shares are down 9.5% at $5.35 on only about 12,000 shares. This is rarely a stock that trades in the pre-market.

National Bank of Greece SA (NYSE: NBG) is seeing a major pop up this morning despite a Goldman Sachs downgrade that is way too late. This is on the major overhaul proposed. Shares are up 10% at $3.77 on about 40,000 shares.

Sequenom, Inc. (NASDAQ: SQNM) is trading up over 5% at $4.35 this morning on 60,000 shares after the company reported that it licensed the worldwide rights to develop age-related macular degeneration diagnostic test to Optherion and is expected to launch in 2011.

You are invited to join our free daily email distribution list to hear about top analyst upgrades and downgrades, IPOs and secondary offerings, ongoing day trader and options trader alerts, stock and market rumors, Buffett and guru investor news, M&A and more.

Price snapshots as of 8:40 to 8:50 AM EST

JON C. OGG
FEBRUARY 9, 2010

Amgen Soft on FDA Data (AMGN)

247admin — Mon, 19 Oct 2009 12:43:40 +0000

Amgen Inc. (NASDAQ: AMGN) was on deck for an FDA decision on its Prolia bone drug. The FDA has effectively delayed its decision to approve the drug with a request for more information. The FDA wants to know how the company will monitor patients using Prolia and it also wants Amgen to develop a strategy to evaluate the risks of Prolia. As of 8:42 AM EST we have shares down 3% at $59.30 on over 540,000 shares. Average volume is almost 7.5 million shares, and this is already better than some of the pre-market trades indicated earlier. JON OGG

Amgen Study Helps (AMGN)

247admin — Mon, 21 Sep 2009 12:53:45 +0000

Amgen, Inc. (NASDAQ: AMGN) is seeing some positive action this morning. The biotech and drug maker announced Phase 3 trial results evaluating denosumab versus Zometa in advanced cancer patients with solid tumors or multiple myeloma showing that denosumab delayed skeletal related events (osteoporosis etc.). Shares are up over 2% at $62.20 on over 175,000 shares as of 8:52 AM EST. As this is already the leader here, the fallout may be limited in competitors. If you can believe it, Amgen is now within about 3% of its 52-week highs. -JON OGG

PREMARKET ALERT: Amgen (AMGN)

247admin — Tue, 28 Jul 2009 11:56:47 +0000

Amgen Inc. (Nasdaq: AMGN) shares fell about 1 percent to $60.33 after hours on Monday with more than 2.3 million shares traded after hours, making it one of the most active Nasdaq stocks. The company posted better-than-expected top and bottom-line result but had disappointing sales of its blockbuster Neulasta. -

UPDATE: Stock is up 2.7 percent to $62.42 in premarket volume of about 130,000 shares as of 9 a.m. Eastern. — Mike Tarsala
See full story at BioHealthInvestor.com

PREMARKET ALERT: Amgen (AMGN, NVS)

247admin — Wed, 08 Jul 2009 11:24:41 +0000

Amgen Inc. (Nasdaq: AMGN) shares are up about 13 percent to around $59 on volume of 16,000 shares in very early premarket trading on Wednesday.

After the close, the company announced positive Phase III trial results of its osteoporosis drug Denosumab. The clinical results were strong enough to possibly make the drug the standard of care to treat patients with metastasized breast cancer, replacing Novartis Inc.’s (NYSE: NVS) Zometa.

Get the complete details at BioHealthInvestor.com.

Top Pre-Market Gap-Ups (AMGN, BEAV, CNQR, UAUA, WBSN)

247admin — Tue, 29 Jul 2008 12:59:26 +0000

Amgen (AMGN) indicating up 3% more after solid earnings… watch for potential profit taking later in the morning after huge gain yesterday.

BE Aerospace (BEAV) is trading up almost 7% after the company managed to beat earnings and raise guidance despite woes at airline carriers themselves; short covering adding to gains.

Concur Technologies, Inc. (CNQR) gapping up 10% after AmEx partnered with the company and took a 13% equity stake in teh company.

UAL Corp (UAUA) up 6% pre-market on trader talk and on oil prices.

Websense (WBSN) trading up 8% after beating earnings and giving solid guidance as acquisition of SurfControl is working well for the company.

(9:02 AM EST)

JON OGG
JULY 29, 2008

52-Week High/Volume Surge: Amgen (AMGN)

247admin — Mon, 28 Jul 2008 12:59:51 +0000

The most active stock in pre-market trading is Amgen Inc. (NASDAQ: AMGN) after the company released its positive data on its osteoporosis treatment that Wall Street was awaiting.

This stock is surging to new 52-week highs and getting out from under a very large shadow since it has had almost nothing but problems since 2006.

Amgen has seen more than 4.7 million shares trade hands (9:04 AM) today with shares up at $61.60. Its prior 52-week high was $59.08. After this news was released late Friday after the close, we saw shares trade over 2.66 million after the close and the last after-hours print Friday was $61.60.

It’s probably a safe bet that with Amgen posting earnings today and with a such a gap up top 52-week highs we’ll be expecting Amgen stock options to be among the most active.

Jon Ogg
July 28, 2008

After-Hours Surge: AMGEN (AMGN)

247admin — Fri, 25 Jul 2008 21:08:06 +0000

Amgen Inc (NASDAQ: AMGN) is surging in after hours trading after the company showed this long-awaited and highly anticipated osteoporosis data.

Shares are up a monster 11% after the close. This takes shares back over $60.00 for the first time in more than a year. To top it off, we have seen more than 900,000 shares trade hands since the close.

Jon Ogg
July 25, 2008